Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02561962 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT02561962 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 42 participants.
The verdict
NCT02561962, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.
Interventions
- DRUG AMG 224
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-11-20 |
| Est. Completion | 2022-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02561962
The ClinicalTrials.gov registry entry for NCT02561962 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 224 is the first listed.
NCT02561962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02561962 about?
NCT02561962 is a clinical study titled "A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma". This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.
What is the current status of trial NCT02561962?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2015-11-20. Estimated completion is 2022-04-21.
What interventions are being tested in trial NCT02561962?
The interventions under investigation include: AMG 224 (DRUG).
Who is sponsoring clinical trial NCT02561962?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.